profit from every $100 of sales.
$0$100
Tekla Life Sciences Investors
$18.28-0.33% today
+9.0% in 1 year
1-year low $15.871-year high $22.67
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $6.49 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Tekla Life Sciences Investors sold, what it kept, and what it did with the cash.
Sales went from -$103 million in 2022 to $86.4 million in 2025, with $85.6 million of profit last year.
SalesProfit
Tekla Life Sciences Investors handed back 100% of the cash it generated last year.
$32M
Free cash flow 2025$32M
Bought back its own shares–
Paid as dividends$32M
Tekla Life Sciences Investors vs. similar companies
Tekla Life Sciences Investors grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tekla Life Sciences Investors | 6.5× · Cheap | ||
 BlackRock | 34.0× · Expensive | ||
 Blackstone | 49.1× · Expensive | ||
 Investor | 8.5× · Cheap | ||
 Brookfield | 70.0× · Very expensive |
AI analysis
An AI analyst reads Tekla Life Sciences Investors's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -103 | 24 | 87 | 86 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| -105 | 22 | 85 | 86 | |
| -4.26 | 0.79 | 3.04 | – | |
| – | – | – | – | |
| – | – | – | – | |
| 101.3% | 95.0% | 98.4% | 99.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 415 | 403 | 461 | 515 |
| Cash | 0 | 0 | 0 | 0 |
| Total debt | – | – | – | – |
| Total liabilities | 17 | 1 | 1 | 2 |
| 398 | 402 | 460 | 514 | |
| 25 | 28 | 28 | – | |
| – | – | – | – | |
| -26.3% | 5.6% | 18.6% | 16.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | 32 | |
| – | – | – | – | |
| – | – | – | 32 | |
| Dividends paid | – | – | – | 32 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 6.5×
- –
- –
- 1.0×
- 6.4×
- 17.5×
- –
- 5.7%
- 15.4%
- 11.9%
Profitability
- 30.8%
- 286.9%
- 99.1%
- 286.9%
- 16.6%
- 5.5%
- 18.8%
- 16.6%
- 16.6%
- –
Growth
- +91.6%
- –
- –
- +3.1%
- +4.4%
Financial health
- -0.0×
- 0.00
- 0.0%
- –
- 1.74
- 1.74
- 0.06
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 848
Top 11%of 880
Top 3%of 878
Bottom 47%of 932
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Jun 24, 2025 | -1.64 | – | – |
| Dec 9, 2024 | 1.22 | – | – |
| Aug 6, 2024 | 1.84 | – | – |
| Dec 11, 2023 | -0.43 | – | – |
| Mar 31, 2023 | 1.29 | – | – |
| Sep 30, 2022 | -1.10 | – | – |
| Mar 31, 2022 | -3.03 | – | – |
| Sep 30, 2021 | 1.34 | – | – |
11.9%of the share price, paid each year
On $1,000 invested$119a year at today's yield, before tax
+3.1%2020 to 2025
Raised–not every year
Paid per share, each year
$2.80 in 2015 → $1.82 in 2025
How safe it looks
37.0% of its profit
Room to growStretchedMore than it earns: 99.8%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
77Pass
Philip Fisher
55No pass
Peter Lynch
100Pass
Joel Greenblatt
55No pass
Charlie Munger
50No pass
Terry Smith
43No pass
Questions about Tekla Life Sciences Investors
Is Tekla Life Sciences Investors a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tekla Life Sciences Investors AI analysis
What does Tekla Life Sciences Investors do?
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It is in Asset Management.
Does Tekla Life Sciences Investors pay a dividend?
Yes. At today's price the dividend is 11.9% a year, about 37% of its yearly profit. In 2025 it paid out $31.6 million in dividends.
Is Tekla Life Sciences Investors stock halal?
Yes. Tekla Life Sciences Investors passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Tekla Life Sciences Investors stock done over the past year?
Up 9.0% over the past twelve months, to $18.28. It traded between $15.87 and $22.67 and is 19.4% below its high.
Who are Tekla Life Sciences Investors's competitors?
The largest listed companies in the same industry are BlackRock, Blackstone, Investor and Brookfield. The peers table on this page compares their profit, growth and price with Tekla Life Sciences Investors's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.